Villarejo Campos, P.; Sánchez GarcÃa, S.; Amo-Salas, M.; GarcÃa Santos, E.; López de la Manzanara, C.; Alberca, A.; Padilla-Valverde, D.; Redondo Calvo, F.J.; MartÃn, J.
Paclitaxel as HIPEC-Drug after Surgical Cytoreduction for Ovarian Peritoneal Metastases: A Randomized Phase III Clinical Trial (HIPECOVA). Curr. Oncol. 2024, 31, 660-671.
https://doi.org/10.3390/curroncol31020048
AMA Style
Villarejo Campos P, Sánchez GarcÃa S, Amo-Salas M, GarcÃa Santos E, López de la Manzanara C, Alberca A, Padilla-Valverde D, Redondo Calvo FJ, MartÃn J.
Paclitaxel as HIPEC-Drug after Surgical Cytoreduction for Ovarian Peritoneal Metastases: A Randomized Phase III Clinical Trial (HIPECOVA). Current Oncology. 2024; 31(2):660-671.
https://doi.org/10.3390/curroncol31020048
Chicago/Turabian Style
Villarejo Campos, Pedro, Susana Sánchez GarcÃa, Mariano Amo-Salas, Esther GarcÃa Santos, Carlos López de la Manzanara, Ana Alberca, David Padilla-Valverde, Francisco Javier Redondo Calvo, and Jesús MartÃn.
2024. "Paclitaxel as HIPEC-Drug after Surgical Cytoreduction for Ovarian Peritoneal Metastases: A Randomized Phase III Clinical Trial (HIPECOVA)" Current Oncology 31, no. 2: 660-671.
https://doi.org/10.3390/curroncol31020048
APA Style
Villarejo Campos, P., Sánchez GarcÃa, S., Amo-Salas, M., GarcÃa Santos, E., López de la Manzanara, C., Alberca, A., Padilla-Valverde, D., Redondo Calvo, F. J., & MartÃn, J.
(2024). Paclitaxel as HIPEC-Drug after Surgical Cytoreduction for Ovarian Peritoneal Metastases: A Randomized Phase III Clinical Trial (HIPECOVA). Current Oncology, 31(2), 660-671.
https://doi.org/10.3390/curroncol31020048
